95 related articles for article (PubMed ID: 18299479)
21. Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23.
Lee JY; Park HS; Han S; Lim JK; Hong N; Park SI; Rhee Y
Yonsei Med J; 2017 Sep; 58(5):981-987. PubMed ID: 28792142
[TBL] [Abstract][Full Text] [Related]
22. [Hypophosphatemic osteomalacia].
Bullmann C; Benker G; Rosien U; Delling G; Siggelkow H; Schulte HM
Med Klin (Munich); 2008 Sep; 103(9):671-5. PubMed ID: 18813890
[TBL] [Abstract][Full Text] [Related]
23. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
Burnett SM; Gunawardene SC; Bringhurst FR; Jüppner H; Lee H; Finkelstein JS
J Bone Miner Res; 2006 Aug; 21(8):1187-96. PubMed ID: 16869716
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
25. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
Bhan I; Shah A; Holmes J; Isakova T; Gutierrez O; Burnett SM; Jüppner H; Wolf M
Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
[TBL] [Abstract][Full Text] [Related]
26. Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia.
Han SY; Hwang EA; Park SB; Kim HC; Kim HT
Transplant Proc; 2012 Apr; 44(3):657-60. PubMed ID: 22483462
[TBL] [Abstract][Full Text] [Related]
27. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.
Barros X; Torregrosa JV; Martínez de Osaba MJ; Casals G; Paschoalin R; Durán CE; Campistol JM
Transplantation; 2012 Oct; 94(8):830-6. PubMed ID: 23018879
[TBL] [Abstract][Full Text] [Related]
28. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
29. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
30. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna.
Ward LM; Rauch F; White KE; Filler G; Matzinger MA; Letts M; Travers R; Econs MJ; Glorieux FH
Bone; 2004 May; 34(5):905-11. PubMed ID: 15121023
[TBL] [Abstract][Full Text] [Related]
31. A paranasal tumor associated with tumor-induced osteomalacia.
Inokuchi G; Tanimoto H; Ishida H; Sugimoto T; Yamauchi M; Miyauchi A; Nibu K
Laryngoscope; 2006 Oct; 116(10):1930-3. PubMed ID: 17003734
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
[TBL] [Abstract][Full Text] [Related]
33. Unilateral primary ovarian leiomyoma in adolescent: a case report.
Güney M; Ozsoy M; Oral B; Mungan T; Kapucuoğlu N
Arch Gynecol Obstet; 2007 Jun; 275(6):507-10. PubMed ID: 17139489
[TBL] [Abstract][Full Text] [Related]
34. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
[TBL] [Abstract][Full Text] [Related]
35. Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor.
Bohlmann MK; Rabe T; Sinn HP; Strowitzki T; Von Wolff M
Gynecol Endocrinol; 2005 Sep; 21(3):138-41. PubMed ID: 16335905
[TBL] [Abstract][Full Text] [Related]
36. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.
Fassbender WJ; Brandenburg V; Schmitz S; Sandig D; Simon SA; Windolf J; Stumpf UC
Clin Lab; 2009; 55(3-4):144-52. PubMed ID: 19462937
[TBL] [Abstract][Full Text] [Related]
38. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis.
Domrongkitchaiporn S; Disthabanchong S; Cheawchanthanakij R; Niticharoenpong K; Stitchantrakul W; Charoenphandhu N; Krishnamra N
Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):105-12. PubMed ID: 19449283
[TBL] [Abstract][Full Text] [Related]
39. Osteomalacia induced by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23.
Nagae K; Uchi H; Ito T; Moroi Y; Oda Y; Furue M
Eur J Dermatol; 2015 Apr; 25(2):199-200. PubMed ID: 25788099
[No Abstract] [Full Text] [Related]
40. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
Shimada T; Hasegawa H; Yamazaki Y; Muto T; Hino R; Takeuchi Y; Fujita T; Nakahara K; Fukumoto S; Yamashita T
J Bone Miner Res; 2004 Mar; 19(3):429-35. PubMed ID: 15040831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
